Navigating the changing landscape of severe asthma management

Sponsored by Novartis Pharmaceuticals Australia Pty Ltd

For a long time, a lack of new treatment options has left respiratory physicians ‘plugging the holes’ in the leaky bucket that is severe asthma. But over the last few years a number of novel treatments, including monoclonal antibodies, have acquired Pharmaceutical Benefits Scheme (PBS) funding.1 Importantly, additional, innovative small molecule inhibitors are under clinical ...

Already a member?

Login to keep reading.

© 2021 the limbic